Log in

Relevant bibliographies by topics / Mesenchynol stronel cels / Books

To see the other types of publications on this topic, follow the link: Mesenchynol stronel cels.

Books on the topic 'Mesenchynol stronel cels'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 20 books for your research on the topic 'Mesenchynol stronel cels.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Hematti, Peiman, and Armand Keating, eds. Mesenchymal Stromal Cells. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-5711-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gross, Gerhard, and Thomas Häupl. Stem cell-dependent therapies: Mesenchymal stem cells in chronic inflammatory disorders. Berlin: De Gruyter, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Zhao, Robert Chunhua. Essentials of mesenchymal stem cell biology and its clinical translation. Dordrecht: Springer, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mesenchymal Stromal Cells. Elsevier, 2017. http://dx.doi.org/10.1016/c2014-0-03703-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mesenchymal Stromal Cells as Tumor Stromal Modulators. Elsevier, 2017. http://dx.doi.org/10.1016/c2014-0-03622-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mesenchymal Stromal Cells Biology And Clinical Applications. Springer-Verlag New York Inc., 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

J, Prockop Darwin, Phinney Donald G, and Bunnell Bruce A, eds. Mesenchymal stem cells: Methods and protocols. Totowa, NJ: Humana Press, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Keating, Armand, and Peiman Hematti. Mesenchymal Stromal Cells: Biology and Clinical Applications. Humana Press, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Keating, Armand, and Peiman Hematti. Mesenchymal Stromal Cells: Biology and Clinical Applications. Humana, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Stem Cell Therapeutics for Cancer. Wiley-Blackwell, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Viswanathan, Sowmya, and Hematti Peiman. Mesenchymal Stromal Cells: Translational Pathways to Clinical Adoption. Elsevier Science & Technology Books, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

da Silva Meirelles, Lindolfo, Karen Bieback, and Marcela F. Bolontrade, eds. Current Progress in Mesenchymal Stem/Stromal Cell Research. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88966-625-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Morrison, Randy. Mesenchymal Stromal Cells: Biology, Mechanisms of Action and Clinical Uses. Nova Science Publishers, Incorporated, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Mesenchymal Stem Cell Therapy Stem Cell Biology and Regenerative Medicine. Humana Press, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

(Editor), Darwin J. Prockop, Donald G. Phinney (Editor), and Bruce A. Bunnell (Editor), eds. Mesenchymal Stem Cells: Methods and Protocols (Methods in Molecular Biology). Humana Press, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

1948-, Goldberg I. D., and Rosen E. M, eds. Epithelial-mesenchymal interactions in cancer. Basel: Birkhäuser Verlag, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Resident Stem Cells And Regenerative Therapy. Academic Press, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Tyndall, Alan, and Jacob M. van Laar. Stem cell therapies. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0085.

Full text

Abstract:

Since the start of the international project in 1997, over 1500 patients have received a haematopoietic stem cell transplant (HSCT), mostly autologous, as treatment for a severe autoimmune disease, with overall 85% 5-year survival and 43% progression-free survival. Around 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many cases, e.g. systemic sclerosis, morphological improvement such as reduction of skin collagen and normalization of microvasculature was documented, beyond any predicted known effects of intense immunosuppression alone. It is hoped that the results of the three running large prospective randomized controlled trials will allow modification of the protocols to reduce the high transplant-related mortality which relates to regimen intensity, age of patient, and comorbidity. Multipotent mesenchymal stromal cells (MSC) have been recently tested in various autoimmune diseases, exploiting their immune modulating properties and apparent low acute toxicity. MSC display immune privilege in that the patient requires no immunosuppression prior to allogeneic MSC infusion. Despite encouraging small phase I/II studies, no positive data from randomized prospective studies are as yet available in the peer-reviewed literature.

APA, Harvard, Vancouver, ISO, and other styles

19

Tyndall, Alan, and Jacob M. van Laar. Stem cell therapies. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0085_update_003.

Full text

Abstract:

Since the start of the international project in 1997, over 2000 patients have received a haematopoietic stem cell transplant (HSCT), mostly autologous, as treatment for a severe autoimmune disease, with overall 85% 5-year survival and 43% progression-free survival. Around 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many cases, e.g. systemic sclerosis, morphological improvement such as reduction of skin collagen and normalization of microvasculature was documented, beyond any predicted known effects of intense immunosuppression alone. It is hoped that the results of the three running large prospective randomized controlled trials will allow modification of the protocols to reduce the high transplant-related mortality which relates to regimen intensity, age of patient, and comorbidity. Multipotent mesenchymal stromal cells (MSC) have been recently tested in various autoimmune diseases, exploiting their immune modulating properties and apparent low acute toxicity. MSC display immune privilege in that the patient requires no immunosuppression prior to allogeneic MSC infusion. Despite encouraging many small phase I/II studies, only 2 prospective controlled trials which achieved their primary endpoints have been published.

APA, Harvard, Vancouver, ISO, and other styles

20

Reader, Jocelyn, Sarah Lynam, Amy Harper, Gautam Rao, Maya Matheny, and Dana M. Roque. Ovarian Tumor Microenvironment and Innate Immune Recognition. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0004.

Full text

Abstract:

Ovarian adenocarcinoma is typified by detection at late stages with dissemination of cancer cells into the peritoneal cavity and frequent acquisition of chemoresistance. A number of studies show the importance of the tumor microenvironment and innate immune recognition in tumor progression. Ovarian cancer cells can regulate the composition of their stroma to promote the formation of ascitic fluid rich in cytokines and bioactive lipids such as PGE2, and to stimulate the differentiation of stromal cells into a pro-tumoral phenotype. In response, cancer-associated fibroblasts, cancer-associated mesenchymal stem cells, tumor-associated macrophages, and other peritoneal cells can act through direct and indirect mechanisms to regulate tumor growth, chemoresistance via alteration of class III β‎ tubulin, angiogenesis and dissemination. This chapter deciphers the current knowledge about the role of stromal cells, associated secreted factors, and the immune system on tumor progression. This suggests that targeting the microenvironment holds great potential to improve the prognosis of patients with ovarian adenocarcinoma.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!